Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, Citigroup Analyst Says

Kymera Therapeutics (NASDAQ:KYMR) had its price objective upped by Citigroup from $110.00 to $120.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Citigroup’s target price would indicate a potential upside of 38.97% from the stock’s previous close.

Several other equities analysts have also issued reports on KYMR. Bank of America boosted their price objective on Kymera Therapeutics from $71.00 to $112.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Guggenheim initiated coverage on shares of Kymera Therapeutics in a research note on Monday, November 3rd. They issued a “buy” rating and a $90.00 price target on the stock. BTIG Research lowered their price objective on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Piper Sandler raised their price objective on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Finally, Oppenheimer upped their target price on shares of Kymera Therapeutics from $67.00 to $120.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $119.50.

Kymera Therapeutics Stock Down 4.2%

KYMR opened at $86.35 on Monday. The stock has a market cap of $7.05 billion, a P/E ratio of -23.46 and a beta of 2.20. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $103.00. The company has a fifty day simple moving average of $78.69 and a 200 day simple moving average of $66.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.20). Kymera Therapeutics had a negative net margin of 794.04% and a negative return on equity of 28.71%. The business had revenue of $2.87 million during the quarter, compared to analyst estimates of $14.80 million. During the same period in the previous year, the firm posted ($0.88) earnings per share. The firm’s revenue was down 60.8% on a year-over-year basis. On average, equities research analysts expect that Kymera Therapeutics will post -2.79 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 678 shares of the business’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $91.04, for a total transaction of $61,725.12. Following the transaction, the director owned 685,393 shares of the company’s stock, valued at $62,398,178.72. The trade was a 0.10% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Jared Gollob sold 49,307 shares of the stock in a transaction that occurred on Monday, December 8th. The shares were sold at an average price of $88.67, for a total value of $4,372,051.69. Following the completion of the sale, the insider directly owned 109,992 shares of the company’s stock, valued at approximately $9,752,990.64. The trade was a 30.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 450,895 shares of company stock valued at $40,486,151 in the last quarter. 16.01% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Kymera Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the company. Baker BROS. Advisors LP lifted its stake in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after acquiring an additional 2,005,813 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in shares of Kymera Therapeutics by 17.7% in the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after purchasing an additional 1,124,747 shares during the period. Vanguard Group Inc. lifted its stake in Kymera Therapeutics by 15.6% in the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after purchasing an additional 845,922 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Kymera Therapeutics by 20.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock worth $479,258,000 after purchasing an additional 1,061,957 shares during the period. Finally, BVF Inc. IL grew its holdings in Kymera Therapeutics by 6.6% during the second quarter. BVF Inc. IL now owns 5,502,710 shares of the company’s stock worth $240,138,000 after purchasing an additional 340,909 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.